Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;6(5):169-84.
doi: 10.1177/1759720X14551568.

Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know

Megan L Krause  1 , Shreyasee Amin  2 , Ashima Makol  3
Affiliations
Review

Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know

Megan L Krause et al. Ther Adv Musculoskelet Dis. 2014 Oct.

Abstract

Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.

Keywords: DMARDs; biologics; lactation; pregnancy; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: None of the authors have any relevant financial interests to disclose.

References

    1. Amin S., Peterson E., Reed A., Mueller D. (2011) Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. Curr Rheumatol Rep 13: 449–455 - PubMed
    1. Ban L., Tata L., Fiaschi L., Card T. (2014) Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 146: 76–84 - PubMed
    1. Barrett J., Brennan P., Fiddler M., Silman A. (1999) Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheumatism 42: 1219–1227 - PubMed
    1. Bay Bjorn A., Ehrenstein V., Holmager Hundborg H., Aagaard Nohr E., Toft Sorensen H., Norgaard M. (2014) Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Therapeut 21(2): 73–80 - PubMed
    1. Beghin D., Cournot M., Vauzelle C., Elefant E. (2011) Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol 38: 628–632 - PubMed

LinkOut - more resources